Invenio completes enrollment in 1,006-patient AI lung biopsy study
Invenio Imaging enrolled 1,006 patients in its U.S. pivotal study of NIO Lung Cancer Reveal, collecting more than 3,250 fresh biopsy specimens for validation of the investigational AI system.
By Ryan Merket · Published
Primary source: PR Newswire
Why it matters
Invenio is testing whether imaging hardware and AI can give pulmonologists useful biopsy feedback without waiting for specialized pathology staff.
Jay Trautman and Chris Freudiger, the founders of Invenio Imaging, have completed patient enrollment in a pivotal U.S. study of an AI system designed to assess lung biopsy tissue while a bronchoscopy is still underway.…
When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.